Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 24, 2026 08:30 ET | Source: BioMedWire

Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market

AUSTIN, Texas, June 24, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Oncology research is moving through one of its most active stretches in years. DNA Damage Response (“DDR”) inhibitors,...
June 23, 2026 08:30 ET | Source: Onco-Innovations Limited

Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Advancing Nanoparticle-Encapsulated PNKP Inhibitor in Oncology Space

NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) today announces its placement in an editorial published by BioMedWire (BMW), one...
June 22, 2026 08:30 ET | Source: BioMedWire

Next-Generation DNA Repair Therapies Open New Frontiers in Oncology

AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Cancer research is entering one of its most dynamic periods in decades. The class of drugs known as DNA Damage...
June 11, 2026 07:00 ET | Source: Medicenna Therapeutics Corp.

Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms

TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company developing Superkines for...
June 05, 2026 08:30 ET | Source: NetworkNewsWire

NetworkNewsAudio Announces Audio Press Release (APR) Discussing the Exploration of Nanoparticle, Targeted Drug-Delivery Technologies

AUSTIN, Texas, June 05, 2026 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “How Advanced Drug Delivery Could Improve Existing Cancer Treatments,”...
June 02, 2026 08:30 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Advancing Proprietary Solutions Focused on Nanotechnology-Enabled Drug Delivery, AI-Enhanced Biomedical Infrastructure

NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands...
May 18, 2026 08:45 ET | Source: Dogwood Therapeutics, Inc.

Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study

New study to assess Halneuron® pain reduction effect over three months of treatment, additional safety data to bolster planned end of Phase 2 FDA submission package Patients completing the ongoing...
April 15, 2026 09:00 ET | Source: Dogwood Therapeutics, Inc.

Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy

Dogwood licensed SP16 to treat cancer-related pain from partner and regulatory sponsor Serpin Pharma The SP16 Phase 1b trial fully funded by the National Cancer Institute; Patient enrollment expected...
April 09, 2026 07:00 ET | Source: Medicenna Therapeutics Corp.

Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim as Chief Medical Officer

TORONTO and HOUSTON, April 09, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company...
March 18, 2026 08:30 ET | Source: Dogwood Therapeutics, Inc.

Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

ATLANTA, March 18, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and...